BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its HIF-1 alpha (hypoxia-inducible factor 1 alpha) antagonist, a highly-visible, well-validated target in many cancer types, including common solid tumors. The company plans to initiate a phase I trial in the first half of 2007.
